Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.

ABSTRACT:

Background

Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate neoepitope-reactive T-cell identification and validation program that supports the development of next-generation immunotherapies.

Methods

Using GPS Cancer, NantOmics research, and The Cancer Genome Atlas databases, we developed a novel bioinformatic-based approach which assesses mutational load, neoepitope expression, human leukocyte antigen (HLA)-binding prediction, and in vitro confirmation of T-cell recognition to preferentially identify targetable neoepitopes. This program was validated by application

SUBMITTER: Reimann H 

PROVIDER: S-EPMC8237736 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature